Momenta Phama (MNTA) Tops Q3 EPS by 5c

Momenta Phama (NASDAQ: MNTA) reported Q3 EPS of ($0.45), $0.05 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $5.55 million versus the consensus estimate of $5.24 million.

“Our focus in 2019 is on the execution of our clinical programs as they advance toward proof of concept,” said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. “Looking ahead to 2020, we anticipate key readouts across our novel auto- and alloimmune programs, including proof-of-concept data from M254 in ITP and nipocalimab in MG. Importantly, both of these agents have the potential to reshape the treatment landscape for a range of large market, IgG-mediated diseases.”

For earnings history and earnings-related data on Momenta Phama (MNTA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Evogene chairman to address dissident shareholders on results call
• Movano (MOVE) Misses Q2 EPS by 195c